Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies how well fluciclovine positron emission tomography (PET)/computed
tomography (CT) and PSMA PET/CT work in helping doctors understand and classify invasive
lobular breast cancer in patients with invasive lobular breast cancer that is suspicious for
or has spread to other places in the body (metastasized). Fluciclovine and PSMA are
radiotracers used in PET/CT imaging scans that emit radiation. The PET/CT scan than picks up
the radiation being released to create a picture from within the body. Information learned
from this study may help researchers learn how to better identify metastatic disease in
invasive lobular breast cancer patients which will impact appropriate staging.